First-line bevacizumab (B) plus paclitaxel (P) in HER2-negative (HER2-ve) metastatic breast cancer (mBC): Efficacy and safety in an Italian multicenter retrospective study

被引：0

作者：

Andreis, D.

Scandurra, G.

Santini, D.

Gucciardino, C.

La Verde, N. M.

Girelli, S.

Alabiso, I.

Saetta, A.

Atzori, F.

Collova, E.

Ferzi, A.

Gori, S.

Lipari, H.

Saggia, C.

Marcon, I.

Generali, D. G.

机构：

[1] AO Ist Ospitalieri Cremona, UO Multidisciplinare Patol Mammaria, Cremona, Italy

[2] Day Hop, Humanitas Ctr Catanese Oncol, Catania, Italy

[3] Univ Campus Biomed Roma, Dipartimento Med Oncol, Rome, Italy

[4] AO Fatebenefratelli & Oftalm, UO Oncol Med, Milan, Italy

[5] Univ Turin, Dipartimento Sci Clin & Biol, Turin, Italy

[6] Fdn Ist San Raffaele D Giglio di Cefalu, UO Oncol, Cefalu, Italy

[7] AOU Cagliari, Struttura Complessa Oncol Med, Cagliari, Italy

[8] Osped Civile Legnano, Legnano, Italy

[9] AO Perugia, Oncol Med, Perugia, Italy

[10] Cannizzaro Hosp, Div Med Oncol, Catania, Italy

[11] AOU Osped Maggiore della Carita, SCDU Oncol, Novara, Italy

[12] AO Osped Circolo, UO Oncol, Varese, Italy

[13] Fdn Macchi, Varese, Italy

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期

关键词：

D O I：

10.1200/jco.2011.29.15_suppl.e11502

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e11502

引用

页数：1

共 50 条

[41] A Delphi consensus and open debate on the role of first-line bevacizumab for HER2-negative metastatic breast cancer [J].

Puglisi, Fabio ;

Bisagni, Giancarlo ;

Ciccarese, Mariangela ;

Fontanella, Caterina ;

Gamucci, Teresa ;

Leo, Luigi ;

Molino, Annamaria ;

Silva, Rosa Rita ;

Marchetti, Paolo .

FUTURE ONCOLOGY, 2016, 12 (22) :2589-2602

[42] MERiDiAN: A phase III, randomized, double-blind study of the efficacy, safety, and associated biomarkers of bevacizumab plus paclitaxel compared with paclitaxel plus placebo, as first-line treatment of patients with HER2-negative metastatic breast cancer [J].

Miles, David ;

Faoro, Leonardo ;

Wang, Yan V. ;

O'Shaughnerary, Joyce .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)

[43] Choice of primary endpoints in first-line phase III trials of HER2-negative or HER2-unknown metastatic breast cancer (MBC). [J].

Kuemmel, Sherko ;

Mueller, Volkmar ;

Lux, Michael P. ;

Weyer, Geerd ;

Pintoffl, Jan P. ;

Jackisch, Christian .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)

[44] Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study [J].

Dieras, Veronique ;

Wildiers, Hans ;

Jassem, Jacek ;

Dirix, Luc Y. ;

Guastalla, Jean-Paul ;

Bono, Petri ;

Hurvitz, Sara A. ;

Goncalves, Anthony ;

Romieu, Gilles ;

Limentani, Steven A. ;

Jerusalem, Guy ;

Lakshmaiah, K. C. ;

Roche, Henri ;

Sanchez-Rovira, Pedro ;

Pienkowski, Tadeusz ;

Segui Palmer, Miguel Angel ;

Li, Ai ;

Sun, Yu-Nien ;

Pickett, Cheryl A. ;

Slamon, Dennis J. .

BREAST, 2015, 24 (03) :182-190

[45] Pooled-analysis of prospective observational studies evaluated the effectiveness and safety of bevacizumab and paclitaxel as the first-line chemotherapy for HER2-negative metastatic breast cancer [J].

Yamashiro, H. ;

Yamamoto, Y. ;

Schneeweiss, A. ;

Mueller, V. ;

Gluz, O. ;

Klare, P. ;

Aktas, B. ;

Magdolna, D. ;

Buedi, L. ;

Piko, B. ;

Mangel, L. ;

Toi, M. ;

Morita, S. ;

Ohno, S. .

ANNALS OF ONCOLOGY, 2020, 31 :S367-S367

[46] Bevacizumab as first-line treatment in HER2-negative advanced breast cancer: pros and cons [J].

Sini, Valentina ;

Cassano, Alessandra ;

Corsi, Domenico ;

De Laurentiis, Michele ;

Gamucci, Teresa ;

Mauri, Mariella ;

Naso, Giuseppe ;

Roselli, Mario ;

Ruggeri, Enzo Maria ;

Tonini, Giuseppe ;

Vici, Patrizia ;

Zampa, Germano ;

Marchetti, Paolo .

TUMORI JOURNAL, 2016, 102 (05) :472-480

[47] Phase II study of gemcitabine (G) and bevacizumab (B) as first-line treatment in taxane-pretreated, HER2-negative, locally recurrent or metastatic breast cancer (MBC) [J].

Borson, R. ;

Harker, W. G. ;

Reeves, J. E. ;

Drosick, D. ;

Beck, J. T. ;

Hager, S. J. ;

Horvath, W. L. ;

Bromund, J. ;

Zeigler, H. ;

Tai, D. ;

Yardley, D. A. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)

[48] Safety and immunologic activity of anakinra in HER2-negative metastatic breast cancer (MBC). [J].

O'Shaughnessy, Joyce ;

Young, Robyn R. ;

Levin, Maren K. ;

Baisch, Jeanine ;

Timis, Roxana ;

Muniz, Luz Stella ;

Turner, Jacob ;

Pascual, Virginia ;

Palucka, Karolina .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)

[49] Factors Associated with the Selection of First-line Bevacizumab plus Chemotherapy and Clinical Response in HER2-negative Metastatic Breast Cancer: ONCOSUR AVALOX Study [J].

Manso, Luis ;

Garcia Palomo, Andres ;

Perez Carrion, Ramon ;

Cassinello, Javier ;

Gallegos Sancho, Isabel ;

Chacon Lopez-Muniz, Ignacio ;

Olier, Clara ;

Fernandez-Aramburo, Antonio ;

Llorca, Cristina ;

Gonzalez, Xavier ;

Llorente, Rosa ;

Torregrosa, Dolores ;

Alvarez, Inaki ;

Galve, Elena ;

Bueno, Coralia ;

Garau, Isabel ;

Garcia, Maria Jose ;

Gonzalez-Santiago, Santiago ;

Ballesteros, Ana Isabel ;

Blanco, Esperanza ;

Galan, Antonio ;

Gonzalez, Sonia ;

Perello, Antonia ;

Cortes-Funes, Hernan ;

Gravalos, Cristina .

ANTICANCER RESEARCH, 2015, 35 (12) :6941-6950

[50] Efficacy and safety of eribulin plus carboplatin combination for HER2-negative metastatic breast cancer [J].

Ni, M. ;

Zhou, L. ;

Lu, Y. ;

Zhang, L. ;

Li, X. ;

Chen, M. ;

Yang, A. ;

Zhang, L. ;

Xu, F. ;

Yuan, Z. ;

Wang, S. ;

Shi, Y. ;

An, X. .

ANNALS OF ONCOLOGY, 2023, 34 :S1490-S1490

← 1 2 3 4 5 →